Cargando…

Health‐related quality of life among transthyretin amyloid cardiomyopathy patients

AIMS: Transthyretin amyloid cardiomyopathy (ATTR CM) is a progressive and severe heart disease with physical and psychological implications. The Nordic PROACT study was conducted to investigate the health‐related quality of life (HRQoL) in ATTR CM patients. METHODS AND RESULTS: The Nordic PROACT stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eldhagen, Per, Lehtonen, Jukka, Gude, Einar, Gustafsson, Finn, Bagger‐Bahnsen, Anne, Vakevainen, Merja, Pilgaard, Trine, Wedell‐Wedellsborg, Dorte, Poulsen, Steen Hvitfeldt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192258/ https://www.ncbi.nlm.nih.gov/pubmed/36946241 http://dx.doi.org/10.1002/ehf2.14350

Ejemplares similares

Suspicion, screening, and diagnosis of wild‐type transthyretin amyloid cardiomyopathy: a systematic literature review
por: Bay, Katrine, et al.
Publicado: (2022)

Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
por: Lauppe, Rosa Elisabeth, et al.
Publicado: (2021)

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
por: Lauppe, Rosa, et al.
Publicado: (2022)

Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries
por: Lauppe, Rosa, et al.
Publicado: (2022)

Wild-type transthyretin amyloid cardiomyopathy: expect the unexpected—a case report
por: Skov, Jens Kæstel, et al.
Publicado: (2023)

Diagnosis of Transthyretin Amyloid Cardiomyopathy
por: Hafeez, Adam S., et al.
Publicado: (2020)

Hereditary transthyretin amyloid cardiomyopathy
por: Zheng, Yiliang, et al.
Publicado: (2023)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis
por: Eldhagen, P., et al.
Publicado: (2021)

Speckle Tracking and Transthyretin Amyloid Cardiomyopathy
por: Rocha, Alexandre Marins, et al.
Publicado: (2017)

Systemic embolism in amyloid transthyretin cardiomyopathy
por: Vilches, Silvia, et al.
Publicado: (2022)

Transthyretin Amyloid Cardiomyopathy: Impact of Transthyretin Amyloid Deposition in Myocardium on Cardiac Morphology and Function
por: Nakano, Tomoya, et al.
Publicado: (2022)

Multi-modality imaging in transthyretin amyloid cardiomyopathy
por: Traynor, Bryan Paul, et al.
Publicado: (2019)

Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
por: Fontana, Marianna, et al.
Publicado: (2023)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
por: Falk, Rodney H., et al.
Publicado: (2021)

Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery
por: Porcari, Aldostefano, et al.
Publicado: (2020)

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
por: Nakamura, Makiko, et al.
Publicado: (2020)

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy
por: Nuvolone, Mario, et al.
Publicado: (2022)

Incidence and Predictors of Ventricular Arrhythmias in Transthyretin Amyloid Cardiomyopathy
por: Knoll, Katharina, et al.
Publicado: (2023)

Opportunistic screening for atrial fibrillation in a real-life setting in general practice in Denmark—The Atrial Fibrillation Found On Routine Detection (AFFORD) non-interventional study
por: Hald, Jonas, et al.
Publicado: (2017)

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
por: Li, Benjamin, et al.
Publicado: (2020)

Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges
por: Bruno, Marianna, et al.
Publicado: (2020)

A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Singh, Bishnu Mohan, et al.
Publicado: (2021)

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Elliott, Perry, et al.
Publicado: (2021)

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges
por: Tschöpe, Carsten, et al.
Publicado: (2022)

Innovation as usual: how to help your people bring great ideas to life
por: Miller, Paddy, et al.
Publicado: (2013)

Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy
por: He, Shan, et al.
Publicado: (2019)

Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
por: Feng, Kent Y., et al.
Publicado: (2019)

Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia
por: Lin, Weiqin, et al.
Publicado: (2022)

Endothelial Function Is Preserved in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy
por: Hashimoto, Yu, et al.
Publicado: (2023)

Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
por: Rettl, René, et al.
Publicado: (2023)

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials
por: Tomasoni, Daniela, et al.
Publicado: (2023)

Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild‐Type Transthyretin Amyloid Cardiomyopathy
por: Morioka, Mami, et al.
Publicado: (2022)

Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
por: Benson, Merrill D, et al.
Publicado: (2015)

Clinical characteristics and natural history of wild‐type transthyretin amyloid cardiomyopathy in Japan
por: Yamada, Toshihiro, et al.
Publicado: (2020)

Estimating the Prevalence of Transthyretin Amyloid Cardiomyopathy in a Large In-Hospital Database in Japan
por: Winburn, Ian, et al.
Publicado: (2019)

Progress in Cardiac Imaging Uncovers the Epidemiology of Wild-Type Transthyretin Amyloid Cardiomyopathy
por: Dorbala, Sharmila, et al.
Publicado: (2021)

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT
por: Nativi‐Nicolau, Jose, et al.
Publicado: (2021)

False‐positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy
por: Chimenti, Cristina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_enco63m31g4mlhr0slnd34a9vh